Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Condition: Non-Small Cell Lung Cancer (NSCLC) · Microsatellite Instability-High (MSI-H) · Non-melanoma Skin Cancer (NMSC) · Sponsor: Replimune, Inc.
About this study
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (51)
| University of Birmingham Alabama | Birmingham, Alabama, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Mayo Clinic | Phoenix, Arizona, United States | — |
| Carti Cancer Center | Little Rock, Arkansas, United States | — |
| UC San Diego | La Jolla, California, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| UCLA | Los Angeles, California, United States | — |
| University of California, Irvine | Orange, California, United States | — |
| University of California- San Francisco | San Francisco, California, United States | — |
| Sylvester Comprehensive Cancer Center- University of Miami | Miami, Florida, United States | — |
| University of Iowa-Cancer Center Research | Iowa City, Iowa, United States | — |
| James Graham Brown Cancer Center- University of Louisville | Louisville, Kentucky, United States | — |
+ 39 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03767348